The studies have highlighted the role of H-Ras mutations in treatment failure or development of resistance to EGFR tyrosine kinase inhibitors such as cetuximab and erlotinib in oral cancer patients [92]. Here, EGFR is linked to lip and oral cavity carcinoma.